Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Tumor-specific CD8+ T cells are exposed to persistent antigenic stimulation which induces a
dysfunctional state called “exhaustion.” Though functioning to limit damage caused by …

The functional decline in T cells during their chronic stimulation, commonly referred to as T
cell exhaustion, is a major limitation for current immunotherapy approaches. As modern …

Tumor immunotherapy is a promising therapeutic strategy for patients with advanced
cancers. T cells are key mediators of antitumor function that specifically recognize and react …

CD8+ T cells are essential lymphocytes with cytotoxic properties for antitumor
immunotherapy. However, during chronic infection or tumorigenesis, these cells often …

In chronic infections and in cancer, persistent antigen stimulation under suboptimal
conditions can lead to the induction of T-cell exhaustion. Exhausted T cells are …

Immunotherapy has revolutionized the treatment of cancer in recent years and achieved
overall success and long‐term clinical benefit in patients with a wide variety of cancer types …

Immune checkpoint therapies (ICT) can reinvigorate the effector functions of anti-tumour T
cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their …

CD8+ T cells play a crucial role in anti‐tumour immunity, but they often undergo exhaustion,
which affects the anti‐tumour activity of CD8+ T cells. The effect and mechanism of …

Immunotherapies have emerged as the most promising area in cancer treatments in recent
years. CD8+ T cells, as one of the primary effector cells of anticancer immunity, however …